22 min
FDA Approval Marks Amivantamab's Milestone in EGFR+ NSCLC Targeted Talks
-
- Health & Fitness
In this episode, Joshua K. Sabari, MD, discusses the FDA approval of amivantamab plus chemotherapy as a first-line treatment for patients with EGFR exon 20 insertion mutation-positive non-small cell lung cancer.
In this episode, Joshua K. Sabari, MD, discusses the FDA approval of amivantamab plus chemotherapy as a first-line treatment for patients with EGFR exon 20 insertion mutation-positive non-small cell lung cancer.
22 min
Top Podcasts In Health & Fitness
On Purpose with Jay Shetty
iHeartPodcasts
The Psychology of your 20s
iHeartPodcasts
Huberman Lab
Scicomm Media
The Mindset Mentor
Rob Dial
Feel Better, Live More with Dr Rangan Chatterjee
Dr Rangan Chatterjee: GP & Author
Real Life Pharmacology - Pharmacology Education for Health Care Professionals
Eric Christianson, PharmD; Pharmacology Expert and Clinical Pharmacist